Skip to main content

Clinical Trials

Neuro-oncologist Yasmeen Rauf meets with a patient in a clinic exam room, reviewing printed materials together. Neuro-Oncology Clinical Trials

The UNC Lineberger Neuro-Oncology Program offers clinical trials for brain and central nervous system cancers that are currently open for patient accrual.

Neuro-Oncology Clinical Trial Study Coordinators

Please contact a study coordinator to learn more about neuro-oncology clinical trials at UNC Lineberger:

Camisha Johnson, MHA
Email: Camisha_Johnson@med.unc.edu

Amalia Postier, MPH, RN, BSN 
Email: Amalia_Postier@med.unc.edu

Randomized Trial of SonoCloud-9 Combined with Carboplatin (CBDCA) versus Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma

SC9-GBM-03 (NCT05902169): For patients experiencing their first progression/recurrence of glioblastomas. Patients are randomized to receive either SonoCloud implant and IV chemotherapy (carboplatin) or standard chemotherapy pill (lomustine versus temozolomide). The SonoCloud implant is activated during chemotherapy infusion visits and uses ultrasound technology to increase permeability of the blood-brain barrier, which allows the chemotherapy to reach residual brain tumor.

Clinical Research Coordinator: Camisha Johnson, MHA
Principal Investigator: Dominique Higgins, MD, PhD

Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

NRG-BN011 (NCT05095376): Patients with methylated MGMT promoter glioblastomas will be randomized into two groups and will receive either a combination of lomustine and temozolomide or temozolomide alone during radiation therapy.

Clinical Research Coordinator: Amalia Postier, MPH, RN, BSN
Principal Investigator: Yasmeen Rauf, MD

Stereotactic Radiosurgery with DDR Inhibitor (Olaparib) Followed by Adjuvant Durvalumab and  Chemotherapy

BRE18-360 (NCT04711824): Patients with brain metastases and triple negative breast cancer will be given olaparib (oral chemotherapy) during radiation followed by a combination of immunotherapy (durvalumab) and physician’s choice of systemic chemotherapy. This study also offers the option to participate in a surgical sub-study where participants only receive olaparib prior to tumor resection and are not given immunotherapy/chemotherapy.

Clinical Research Coordinator: Amalia Postier, MPH, RN, BSN
Principal Investigator: Colette Shen, MD, PhD

Genetic Testing in Guiding Treatment for Patients with Brain Metastases

A071701 NCI CIRB (NCT03994796): For patients with solid tumors and brain metastases, genetic testing of brain tumor is used to guide treatment plan. Patients will be assigned to 1 of 4 oral chemotherapy options based on genetic mutation pathway.

Clinical Research Coordinator: Amalia Postier, MPH, RN, BSN

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma in Unmethylated MGMT Promoter

S22-11168 (NCT06359379): Patients with a new diagnosis of unmethylated MGMT promoter glioblastomas will be randomly assigned to two different doses of ropidoxuridine (oral radio-sensitizer) during six weeks of radiation therapy.

Clinical Research Coordinator: Amalia Postier, MPH, RN, BSN
Principal Investigator: Soma Sengupta, MD, PhD, FRCP, FAAN, FANA

Expanded Access to Gallium Maltolate (GaM) for Adult Patients With Relapsed/Refractory Histologic or Molecular Glioblastoma

IB-EAP-100 (NCT06404034): Patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments will be allowed access for compassionate use of Gallium Maltolate (GaM), an oral therapy at a starting dose of 2000 mg once daily.

Lead Clinical Research Coordinator: Claire Kowalczyk
Principal Investigator: Soma Sengupta, MD, PhD, FRCP, FAAN, FANA

Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma

ETCTN10186: Patients with relapsed/recurrent Grade 2 to 3 meningioma, who have already received radiation therapy and surgery, will be randomized to one of two immunotherapy treatment groups. One treatment arm will receive a combination of immunotherapies (nivolumab + ipilimumab) and the other treatment arm will receive only one type of immunotherapy (nivolumab alone) during reirradiation.

Clinical Research Coordinator: Amalia Postier, MPH, RN, BSN